Authors
Latest:
Treating Patients With Prostate Cancer During COVID-19 Era Poses New ChallengesMonica L. Baskin, PhD, addresses the biggest challenges in treating patients with prostate cancer during the COVID-19 era.
Latest:
Emerging Treatments in Ovarian Cancer and Advice for Community OncologistsDr Chirag A. Shah highlights novel emerging treatments in ovarian cancer and provides advice for community oncologists.
Latest:
Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric CancerYu Sunakawa, MD, PhD, discusses the data observed in the DELIVER trial, which was presented as an updated analysis of nivolumab in patients with advanced gastric cancer at the European Society of Oncology World Congress on Gastrointestinal Cancer 2020.
Latest:
Clinical Pearls and Future Directions of Cervical Cancer TreatmentRitu Salani, MD, offers advice for community oncologists treating patients with cervical cancer and discusses the future directions of the treatment landscape.
Latest:
Advancements Needed in the Esophageal Cancer SpaceAllan Pickens, MD, discusses the current treatment landscape for esophageal cancer.
Latest:
Background of De-Escalation Approach to HER2+ Breast Cancer TreatmentNeil Vasan, MD, PhD, discusses how past studies have supported de-escalated approaches and other improvements to treatment for patients with HER2-positive breast cancer.
Latest:
Lutetium-PSMA-617 and Novel Agents in Prostate CancerOncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.
Latest:
Phase 1/2 Study Tests Quizartinib/Venetoclax/Decitabine in FLT3-ITD AMLMusa Yilmaz, MD, discusses the most recent update of the phase 1/2 study of quizartinib, venetoclax, and decitabine in FLT3-internal tandem duplication mutated acute myeloid leukemia and the background behind this research.
Latest:
Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating AgentsExperts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.
Latest:
Atypical Chronic Myeloid Leukemia: A Rare Disease With Poor PrognosisOngoing research is exploring new molecular targets and targeted therapies for this challenging disease.
Latest:
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney CancerNKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Latest:
Future Directions for the CLL SpaceCarolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.
Latest:
Medical Spending in Community PracticesJosh Weitz, MD, discusses how to balance cost-savings and efficiency while maximizing patient satisfaction in his medical practice.
Latest:
EP. 8B: Reactive and Proactive Treatment Approaches for the Management of Chemotherapy-Induced MyelosuppressionIn this companion article, Dr. Estelamari Rodriguez reflects on the role of reactive and proactive treatment approaches for the management of chemotherapy-induced myelosuppression in small cell lung cancer.
Latest:
Excitement Around Cilta-Cel in Multiple MyelomaYi Lin MD, PhD, discusses the impact of the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of relapsed or refractory multiple myeloma.
Latest:
BPDCN: Future Directions in CareClosing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.
Latest:
Treating Patients With RCC Who Progress Following Adjuvant TherapyThe expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.
Latest:
Predicting the Clinical Trials of the Future: Top 4 Trends to WatchLaura Fernandes, PhD, Senior Statistical Director of COTA, Inc, gives 4 predictions of upcoming trends that will change how clinical trials are performed.
Latest:
Frontline Treatment Options for Patients With BPDCNExplores the intricate decision-making process for frontline treatment in BPDCN patients, with considerations for age, fitness, and various therapeutic approaches.
Latest:
Closing Thoughts on Recent Data in GI Cancers From ESMO 2023Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.
Latest:
Lung Cancer Awareness Month: New Targeted Therapy Options in Advanced NSCLCSurabhi Pathak, MD, reviews current and upcoming targeted treatments in patients with non–small cell lung cancer for Lung Cancer Awareness Month.
Latest:
Can Targeted Therapy Revolutionize MIBC Treatment?Andrea Necchi, MD, discusses how the findings from SunRISe-4 impact other data from the SunRISe group of clinical trials.
Latest:
Differences in Toxicity Based on Race in Nonsquamous NSCLCNino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.
Latest:
Braun Discusses the Role of Biomarkers in RCCDavid Braun, MD, PhD, discusses how biomarkers are evolving for the treatment of renal cell carcinoma.
Latest:
Ontada's EHR Tools Power Real-World Research Solutions in the Community Oncology SettingIn an interview with Targeted Oncology, Robert Reid, MD, discussed how the utilization of Ontada’s solutions helps to improve community-based research across the field of oncology.
Latest:
Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare CancersThe study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.
Latest:
New Liquid Biopsy Method May Improve Upon Current Modalities for Early Detection of CancerVictor Velculescu, MD, PhD, discusses the key takeaways regarding the use of liquid biopsy to detect cancer and a new cfDNA approach to detect cancer at earlier stages.
Latest:
Sabatolimab Appears Promising for Combination Use With HMAs in AML, MDSAndrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
Latest:
Continued Role for Transplantation in NDMMBefore closing out his discussion on newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, emphasizes the continued role of transplantation in this setting.
